Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants
La Jolla Institute for ImmunologyResearchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.